Biotech Values

[DewDiligence]

ABT spinoff factoids re The Global Demographic Tailwind:

• The diversified products successor company (the one that will continue to be called Abbott) will derive 47% of sales from emerging markets in 2014, up from 39% currently.

• ABT’s nutritionals business, which comprises about a quarter of the diversified products successor company, will have $1B of sales in China alone by 2014.

Source: http://media.corporate-ir.net/media_files/irol/94/94004/presentations/Abbott_Investor_Day_2011.pdf